

LA JOLLA PHARMACEUTICAL CO  
 Form 3  
 August 04, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â TANG KEVIN C		(Month/Day/Year)	LA JOLLA PHARMACEUTICAL CO [LJPC]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		07/23/2014		
4747 EXECUTIVE DRIVE,Â SUITE 510			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
			<input type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below) (specify below)	
SAN DIEGO,Â CAÂ 92121			6. Individual or Joint/Group Filing(Check Applicable Line)	
(City)	(State)	(Zip)	<input type="checkbox"/> Form filed by One Reporting Person	
			<input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,699,067	I <u>(1)</u>	By LP <u>(1)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title			

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Series C-1(2) Convertible Preferred Stock	01/19/2012 <sup>(2)</sup>	Â <sup>(3)</sup>	Common Stock 6,167,289	\$ <sup>(4)</sup>	I <sup>(1)</sup>	By LP <sup>(1)</sup>

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TANG KEVIN C 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO, CA 92121	Â	Â	Â	Â
TANG CAPITAL MANAGEMENT LLC 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO, CA 92121	Â	Â	Â	Â
TANG CAPITAL PARTNERS LP 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO, CA 92121	Â	Â	Â	Â

## Signatures

/s/ Kevin C. Tang	**Signature of Reporting Person	08/04/2014
		Date
/s/ Kevin C. Tang, Managing Member	**Signature of Reporting Person	08/04/2014
		Date
/s/ Kevin C. Tang, Managing Member of Tang Capital Management LLC, General Partner	**Signature of Reporting Person	08/04/2014
		Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital
- (1) Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.
  - (2) The Series C-1(2) Convertible Preferred Stock (the "Series C Stock") can only be converted into Common Stock to the extent that, after such conversion, the holder would beneficially own no more than 9.999% of the issuer's Common Stock. As such, none of the Series C Stock reported herein is currently convertible into the issuer's Common Stock.
  - (3) The Series C Stock has no expiration date.
  - (4) Each share of Series C Stock is convertible into the issuer's Common Stock at a rate of 1,724 shares of Common Stock for each share of Series C Stock tendered for conversion.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

## Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.